Article
Interleukin-28B polymorphism improves viral kinetics and is the strongest pretreatment predictor of sustained virologic response in genotype 1 hepatitis C virus.
Gastroenterology - 1 Jul 2010
Thompson Alexander J, Muir Andrew J, Sulkowski Mark S, Ge Dongliang, Fellay Jacques, Shianna Kevin V, Urban Thomas, Afdhal Nezam H, Jacobson Ira M, Esteban Rafael, Poordad Fred, Lawitz Eric J, McCone Jonathan, Shiffman Mitchell L, Galler Greg W, Lee William M, Reindollar Robert, King John W, Kwo Paul Y, Ghalib Reem H, Freilich Bradley, Nyberg Lisa M, Zeuzem Stefan, Poynard Thierry, Vock David M, Pieper Karen S, Patel Keyur, Tillmann Hans L, Noviello Stephanie, Koury Kenneth, Pedicone Lisa D, Brass Clifford A, Albrecht Janice K, Goldstein David B, McHutchison John G
Abstract excerpt
BACKGROUND & AIMS: We recently identified a polymorphism upstream of interleukin (IL)-28B to be associated with a 2-fold difference in sustained virologic response (SVR) rates to pegylated interferon-alfa and ribavirin therapy in a large cohort of treatment-naive, adherent patients with chronic h...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.